$46 B

BSX Mkt cap, 11-Jul-2018

$2.4 B

Boston Scientific Corporation Revenue Q1, 2018
Boston Scientific Corporation Gross profit (Q1, 2018)1.7 B
Boston Scientific Corporation Gross profit margin (Q1, 2018), %71.8%
Boston Scientific Corporation Net income (Q1, 2018)298 M
Boston Scientific Corporation EBIT (Q1, 2018)407 M
Boston Scientific Corporation Cash, 31-Mar-2018287 M
Boston Scientific Corporation EV50.5 B

Boston Scientific Corporation Revenue

Boston Scientific Corporation revenue was $8.39 b in FY, 2016 which is a 12.2% year over year increase from the previous period.

Embed Graph

Boston Scientific Corporation Revenue Breakdown

Embed Graph

Boston Scientific Corporation revenue breakdown by business segment: 35.3% from MedSurg, 24.8% from Rhythm Management and 39.9% from Cardiovascular

Boston Scientific Corporation Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

7.1 b7.4 b7.5 b8.4 b

Revenue growth, %

3%1%12%

Cost of goods sold

2.2 b2.2 b2.2 b2.4 b

Gross profit

5 b5.2 b5.3 b6 b

Gross profit Margin, %

70%70%71%71%

EBIT

120 m(301 m)(327 m)447 m

EBIT margin, %

2%(4%)(4%)5%

Interest expense

324 m216 m284 m233 m

Pre tax profit

(223 m)(509 m)(650 m)177 m

Income tax expense

(102 m)(390 m)(411 m)(170 m)

Net Income

(121 m)(119 m)(239 m)347 m

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

1.7 b1.8 b1.9 b1.8 b1.8 b1.8 b1.9 b2 b2.1 b2.1 b2.2 b2.3 b2.4 b

Cost of goods sold

510 m537 m563 m550 m520 m540 m539 m573 m639 m594 m650 m632 m672 m

Gross profit

1.2 b1.2 b1.3 b1.3 b1.2 b1.3 b1.3 b1.4 b1.5 b1.5 b1.5 b1.6 b1.7 b

Gross profit Margin, %

71%70%70%70%71%71%71%71%70%72%70%72%72%

R&D expense

217 m191 m206 m212 m192 m220 m221 m210 m222 m232 m235 m244 m261 m

General and administrative expense

658 m666 m743 m741 m668 m700 m729 m716 m779 m772 m794 m815 m860 m

Operating expense total

875 m857 m949 m953 m860 m920 m950 m926 m1 b1 b1 b1.1 b1.1 b

Depreciation and amortization

141 m

EBIT

103 m197 m(69 m)64 m24 m219 m(299 m)293 m(334 m)348 m364 m225 m407 m

EBIT margin, %

6%11%(4%)3%1%12%(16%)15%(16%)17%17%10%17%

Interest expense

137 m54 m53 m54 m60 m106 m58 m59 m59 m58 m57 m58 m61 m

Pre tax profit

(40 m)146 m(104 m)3 m(51 m)105 m(367 m)228 m(397 m)257 m305 m91 m323 m

Income tax expense

(35 m)13 m(108 m)(40 m)(50 m)3 m(169 m)26 m(190 m)29 m15 m(55 m)26 m

Net Income

(5 m)133 m4 m43 m(1 m)102 m(198 m)202 m(207 m)228 m290 m146 m298 m

Boston Scientific Corporation Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

217 m587 m319 m196 m

Inventories

897 m946 m1 b955 m

Current Assets

3 b3.6 b3.5 b3.2 b

PP&E

1.5 b1.5 b1.5 b1.6 b

Goodwill

5.7 b5.9 b6.5 b6.7 b

Total Assets

16.6 b17 b18.1 b18.1 b

Accounts Payable

246 m262 m209 m447 m

Current Liabilities

1.8 b2.8 b2.4 b3.6 b

Long-term debt

4.2 b3.9 b5.7 b5.4 b

Total Debt

4.2 b3.9 b5.7 b5.4 b

Additional Paid-in Capital

16.6 b16.7 b16.9 b17 b

Retained Earnings

(8.6 b)(8.7 b)(8.9 b)(8.6 b)

Total Equity

6.5 b6.5 b6.3 b6.7 b

Debt to Equity Ratio

0.6 x0.6 x0.9 x0.8 x

Debt to Assets Ratio

0.3 x0.2 x0.3 x0.3 x

Financial Leverage

2.5 x2.6 x2.9 x2.7 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

571 m191 m357 m246 m242 m903 m350 m338 m438 m237 m156 m195 m287 m

Accounts Receivable

1.2 b1.2 b1.3 b1.2 b1.2 b1.2 b1.3 b1.3 b1.4 b1.4 b1.4 b1.4 b1.6 b

Inventories

895 m926 m949 m989 m958 m968 m1.1 b1 b981 m998 m971 m1 b1.1 b

Current Assets

3.5 b2.9 b3.2 b3.2 b3.2 b3.8 b3.5 b3.2 b3.3 b3.2 b3 b3.2 b4.1 b

PP&E

1.5 b1.5 b1.5 b1.5 b1.5 b1.5 b1.5 b1.5 b1.5 b1.5 b1.7 b1.7 b1.7 b

Goodwill

5.6 b5.7 b5.7 b5.9 b5.9 b5.9 b6.5 b6.5 b6.5 b6.5 b6.7 b6.9 b7 b

Total Assets

16.9 b16.3 b16.5 b16.7 b16.5 b17.1 b18.2 b17.7 b17.8 b17.7 b17.9 b18.4 b19.2 b

Accounts Payable

238 m241 m241 m234 m228 m191 m210 m232 m284 m298 m376 m376 m404 m

Current Liabilities

1.9 b1.7 b1.8 b1.8 b2.5 b1.9 b2.2 b2.6 b3.2 b3 b3.5 b4.3 b5 b

Long-term debt

4.2 b4.2 b4.3 b4.2 b3.8 b5.1 b5.8 b5.4 b5.2 b5.2 b5.5 b4.8 b4.8 b

Total Debt

4.2 b4.2 b4.3 b4.2 b3.8 b5.1 b5.8 b5.4 b5.2 b5.2 b5.5 b4.8 b4.8 b

Additional Paid-in Capital

16.5 b16.6 b16.6 b16.7 b16.8 b16.8 b16.8 b16.8 b16.9 b17 b17 b17.1 b17.2 b

Retained Earnings

(8.7 b)(8.4 b)(8.4 b)(8.4 b)(8.7 b)(8.6 b)(8.8 b)(8.7 b)(8.9 b)(8.7 b)(8.2 b)(8.1 b)(8.3 b)

Total Equity

6.6 b6.4 b6.5 b6.2 b6.5 b7.1 b7.2 b7 b

Financial Leverage

2.6 x2.8 x2.7 x2.9 x2.7 x2.5 x2.5 x2.7 x

Boston Scientific Corporation Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(121 m)(119 m)(239 m)347 m

Accounts Receivable

(101 m)53 m(17 m)(216 m)

Inventories

(7 m)(81 m)3 m40 m

Accounts Payable

(37 m)620 m(20 m)553 m

Cash From Operating Activities

1.1 b1.3 b600 m972 m

Purchases of PP&E

(245 m)(259 m)(247 m)(376 m)

Interest Paid

329 m221 m283 m233 m

Income Taxes Paid

67 m74 m80 m94 m

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015

Net Income

(5 m)133 m4 m43 m(1 m)

Boston Scientific Corporation Ratios

USDY, 2018

EV/EBIT

124.1 x

Financial Leverage

2.7 x
Report incorrect company information

Boston Scientific Corporation Operating Metrics

Boston Scientific Corporation's Customers was reported to be 35 k in FY, 2016.
FY, 2016

Countries

120

Customers

35 k

Facilities

13
Report incorrect company information